Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?

This article was originally published in The Pink Sheet Daily

Executive Summary

Courts have issued mixed rulings in cases challenging FDA restrictions on drug promotion, but with oral arguments set for July 7, Amarin’s suit could provide a definitive answer on what companies can tell physicians.

You may also be interested in...

Trump Administration's Rx Drug Price Disclosure Reg Seen As Unworkable

Lawyers say CMS proposed rule requiring TV ads to disclose drug's list price wouldn't survive First Amendment suit and competitors have no reason to try to enforce it.

Off-Label Promotion Seems On Track: Judge Supportive Of Amarin, Skeptical Of FDA

Oral arguments didn't go particularly well for the agency in its effort to limit what Amarin can tell doctors about unapproved use of Vascepa.

FDA Guidance On Health Care Economic Data Is Coming In 2015

Agency originally said it would issue a draft guidance on industry’s interactions with formulary committees in 2014, but CDER Director Woodcock says “extremely contentious” issues have slowed progress.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts